<code id='1BB974217D'></code><style id='1BB974217D'></style>
    • <acronym id='1BB974217D'></acronym>
      <center id='1BB974217D'><center id='1BB974217D'><tfoot id='1BB974217D'></tfoot></center><abbr id='1BB974217D'><dir id='1BB974217D'><tfoot id='1BB974217D'></tfoot><noframes id='1BB974217D'>

    • <optgroup id='1BB974217D'><strike id='1BB974217D'><sup id='1BB974217D'></sup></strike><code id='1BB974217D'></code></optgroup>
        1. <b id='1BB974217D'><label id='1BB974217D'><select id='1BB974217D'><dt id='1BB974217D'><span id='1BB974217D'></span></dt></select></label></b><u id='1BB974217D'></u>
          <i id='1BB974217D'><strike id='1BB974217D'><tt id='1BB974217D'><pre id='1BB974217D'></pre></tt></strike></i>

          fashion

          fashion

          author:comprehensive    Page View:2438
          Sen. Bob Menendez (D-N.J.) Michael M. Santiago/Getty Images

          WASHINGTON — With mounting calls for embattled Sen. Bob Menendez to resign, the pharmaceutical industry could see one of its historical, and increasingly rare, Democratic allies ousted from Congress.

          The New Jersey senator is embroiled in another financial scandal after last week’s indictment over hundreds of thousands of dollars he and his wife allegedly accepted to influence military aid. The charges — which Menendez insists he will beat — come roughly seven years after he was accused of pressuring Medicare officials to resolve a dispute in favor of a lavish political donor. That case ended in a hung jury.

          advertisement

          But this time around, Capitol lawmakers and New Jersey Democrats including Sen. Cory Booker, a longtime legislation partner, are calling on Menendez to resign. The mounting pressure and looming court battle spell out a hazy future for one of the pharmaceutical industry’s biggest allies in the Democratic Party.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Readout Newsletter: Parkinson's study, Gilead, CG Oncology
          Readout Newsletter: Parkinson's study, Gilead, CG Oncology

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Readout Newsletter: Parkinson's study, Gilead, CG Oncology

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo